Colossal Biosciences
Genetic engineering and genomics technologies for de-extinction projects, including work on the woolly mammoth, thylacine and dodo. The company says they also apply to species preservation and human healthcare.
Health & biotechDe-extinction and genetic engineering biotechDallas, United States
FoundersSince 2021
- Valuation
- $10B
- Total raised
- $615M
- Last round · Feb 2026
- Series C extension
- Founded
- 2021
- Employees
- 170
- Quarters in VP50
- 4
Valuation
| Round | Date | Post-money valuation | Raised | Led by |
|---|---|---|---|---|
| Series B | Jan 31, 2023 | $1.5B | $150M | United States Innovative Technology Fund (USIT) |
| Series C | Jan 15, 2025 | $10B | $200M | TWG Global |
| Series C extension | Sep 17, 2025 | $10B | $120M | Unknown |
Post-money valuation at each priced round. Log scale.Hover a point for the round
Updated
In VP50
- Q4 2023: no place
- Q1 2024: no place
- Q2 2024: no place
- Q3 2024: no place
- Q4 2024: no place
- Q1 2025: #36
- Q2 2025: #42
- Q3 2025: #43
- Q4 2025: #50
- Q1 2026: no place
- Q2 2026: no place
- Q3 2026: no place
- Q4 2026: no place
Place by quarter since Q4 2023. Best place #36.
Funding rounds
DateRound · leadRaisedValuation
Feb 3, 2026Series C extension · UAE$60M—
Sep 17, 2025Series C extension$120M$10B
Team
Ben LammCo-founder, CEO
George ChurchCo-founder, Lead genetics advisor- Brian BeardCo-founder, Chief legal officer
- Beth ShapiroChief science officer
- Sam SingerCFO
- Andrew PaskChief biology officer
- Matt JamesChief animal officer
